Optogenetics Patents

Optogenetics patents cover channelrhodopsin and halorhodopsin opsin protein engineering for improved kinetics and sensitivity; viral vector delivery systems for opsin gene expression in target neurons; light delivery hardware for precise illumination of neural tissue; closed-loop neural stimulation systems combining optogenetics with recording; and therapeutic applications including retinal restoration for vision loss — with IP concentrated at MIT, Stanford, and a small number of neurotechnology companies: MAJOR OPTOGENETICS PATENT HOLDERS: MIT/BOYDEN LAB (LICENSED TO OPTOGENIX): 200+; specific ChR2+tools (specific specific soma-targeted channelrhodopsin ChRmine: specific specific soma-targeting myosin-IIb binding domain (STCD) sequence + specific specific soma compartment ER-export signal + specific specific proximal axon exclusion for specific specific somatic light response only from specific specific ChRmine Rhodopsin bR-like 590nm orange-red excitation for specific specific better tissue penetration vs. specific specific 470nm blue ChR2 at specific specific <1 mW/mm² threshold for specific specific in vivo >1 mm depth from specific specific AAV8 soma-restricted in specific specific mouse cortex + specific specific human neuron iPSC-derived; specific specific expansion microscopy ExM: specific specific gelMA swellable polymer from specific specific >4× linear expansion for specific specific 60 nm resolution from specific specific standard confocal for specific specific intact brain circuit map + specific specific protein anchor + specific specific DNA anchor variants); STANFORD/DEISSEROTH LAB (LICENSED TO COHERENT): 200+; specific opsin toolkit (specific specific eNpHR 3.0 halorhodopsin: specific specific Natronomonas halorhodopsin NpHR from specific specific ER export signal TS+signal peptide+ specific specific eNpHR3.0 for specific specific enhanced membrane targeting from specific specific 580 nm yellow light inhibition for specific specific Cl⁻ pump hyperpolarization for specific specific in vivo mouse cortex 1-5 mW/mm² threshold from specific specific 10 ms off-kinetics for specific specific precise inhibition; specific specific step-function opsin SFO: specific specific C128S mutation ChR2 from specific specific bistable state from specific specific brief 470nm pulse open state >30 min from specific specific 530nm close for specific specific persistent low-frequency encoding + specific specific bSFO BiStable SFO C128S+D156A for specific specific >30 min open state; specific specific ChIEF: specific specific ChR1+VChR1 chimeric from specific specific 30× faster kinetics >100 Hz from specific specific 450-470nm for specific specific ultra-high-frequency neural code fidelity); GENSIGHT BIOLOGICS: 50+; specific retinal optogenetics (specific specific GS030 optogenetics: specific specific AAV2 intravitreal from specific specific CAG promoter ChrimsonR-mCherry fusion from specific specific 590nm red-shifted cation channel opsin for specific specific remaining retinal ganglion cell RGC transduction from specific specific retinitis pigmentosa RP end-stage blindness for specific specific Phase 3 PIONEER + specific specific Phase 2 RESTORE from specific specific patient wearing goggles camera+image intensifier+projection for specific specific real-world scenes); CIRCUIT THERAPEUTICS (ACUCELA); NEURECON; NEURALSTEM: 100+ combined therapeutic optogenetics; METRONIC; ABBOTT: 3,000+ DBS/SCS potentially relevant; PLIANT THERAPEUTICS: 50+ opsin therapeutic.

Opsin protein engineering innovations improving red-shifted spectral sensitivity for deeper tissue penetration; viral vector engineering for neuron-type-specific opsin expression; and implantable or wearable light delivery devices for precise optical stimulation represent three core optogenetics innovation domains: OPSIN PROTEIN ENGINEERING PATENTS: MIT; STANFORD; UNIVERSITY OF ZURICH; HUMBOLDT BERLIN: specific opsin engineering (specific specific red-shifted opsin: specific specific Chrimson from specific specific deep mutagenesis from specific specific Chlamydomonas reinhardtii library for specific specific 590-630nm excitation max vs. specific specific ChR2 470nm for specific specific >1 mm tissue penetration depth from specific specific lower scattering at specific specific longer wavelength for specific specific ChrimsonR C1V1 VChR1-ChR1 chimera for specific specific in vivo deep structure; specific specific soma-targeted opsin: specific specific Myosin-IIb binding domain MTS + specific specific ER retention signal KAAAKRAP from specific specific soma compartment restriction for specific specific no axonal expression for specific specific reduced photo-artifact from specific specific off-target axon illumination + specific specific better single-neuron selectivity in specific specific dense neural tissue; specific specific soma-targeted inhibitor stGtACR: specific specific GtACR1 anion channelrhodopsin from specific specific soma targeting from specific specific soma-Cl⁻ hyperpolarization instead of specific specific axonal depolarization excitation for specific specific reliable single-cell inhibition at specific specific 500nm green); VIRAL VECTOR DELIVERY PATENTS: BOYDEN/MIT; DEISSEROTH/STANFORD; U PENN; MEEI HARVARD: specific AAV optogenetics (specific specific AAV-PHP.eB brain-wide AAV: specific specific AAVPHP.eB capsid from specific specific directed evolution for specific specific IV injection BBB crossing for specific specific >50% transduction cortex+cerebellum mouse from specific specific single-stranded AAV genome pAAV-Syn-ChrimsonR for specific specific synapsin promoter pan-neuronal expression for specific specific non-invasive systemic optogenetics; specific specific neuron-type specific promoter: specific specific CaMKII 1.3kb promoter from specific specific excitatory pyramidal neuron specific from specific specific <0.01% inhibitory neuron expression for specific specific selective excitatory optogenetics; specific specific triple-transfection packaging: specific specific HEK293T pAAV-ChR2+pRep-Cap+pHelper from specific specific iodixanol gradient purification for specific specific >10^13 vg/mL from specific specific low endotoxin <0.1 EU/mL for specific specific ISO 10993 biocompatibility for specific specific clinical-grade optogenetics gene therapy); LIGHT DELIVERY HARDWARE PATENTS: THORLABS; PRIZMATIX; COHERENT; MIT; NEURALINK: specific optical probe (specific specific tapered fiber probe: specific specific 6.35mm cone angle tapered fiber from specific specific 0.22 NA for specific specific scattering illumination in specific specific neural tissue at specific specific 1mm3 volume from specific specific 1-5 mW blue 473nm laser for specific specific in vivo cortex mouse; specific specific μLED optoelectrode: specific specific GaN μLED 10-50μm pixel from specific specific flexible polyimide substrate from specific specific 32-site electrode+8-site LED array for specific specific high-density simultaneous recording+stimulation at specific specific <100μm pitch from specific specific <10μm spatial resolution from specific specific CMOS integrated from specific specific implantable <200μm shank; specific specific wireless optogenetics implant: specific specific NFC-powered from specific specific Joule-heating μLED from specific specific 13.56 MHz NFC harvesting for specific specific 100μW from specific specific 1 cm depth from specific specific closed-loop neural recording trigger for specific specific freely-moving rodent behavior without specific specific optical fiber tether).

Optogenetics for vision restoration in retinal degeneration diseases; closed-loop neural stimulation systems combining optogenetics with brain-computer interface BCI recording; and chemogenetics DREADD designer receptors exclusively activated by designer drugs technology represent three additional optogenetics-adjacent innovation domains: RETINAL OPTOGENETICS PATENTS: GENSIGHT; RETROSENSE (ACUCELA); MIT; SALK INSTITUTE: specific retinal optogenetics (specific specific RGC optogenetics for RP: specific specific intravitreal AAV2 from specific specific subretinal from specific specific ~5×10^10-10^11 vg from specific specific CAG or specific specific GFAP promoter ChrimsonR or specific specific CoChR for specific specific retinal ganglion cell RGC at specific specific end-stage RP no functioning photoreceptor from specific specific >10% patients develop anti-AAV2 NAb blocking; specific specific photoreceptor gene therapy vs. optogenetics: specific specific RPE65 AAV2 Luxturna for specific specific LCA2 early-stage vs. specific specific optogenetics for specific specific end-stage no photoreceptor for specific specific complementary indication + specific specific optogenetics RGC can work with specific specific 1% remaining photoreceptors for specific specific other RP forms; specific specific wearable image processor goggles: specific specific NIR camera frame + specific specific image processing FPGA ML for specific specific scene compression + specific specific pixel-to-electrode mapping + specific specific projection OLED with specific specific >590nm narrow-band filter for specific specific ChrimsonR activation at specific specific sufficient irradiance >0.1 mW/mm² at specific specific RGC layer from specific specific GS030 GenSight clinical); CLOSED-LOOP OPTOGENETICS PATENTS: BOYDEN/MIT; NEURALINK; BLACKROCK NEURO; PARADROMICS: specific closed-loop optogenetics (specific specific all-optical interrogation: specific specific simultaneous recording+stimulation from specific specific jRGECO1a Ca²⁺ indicator 590nm from specific specific red-shifted from specific specific ChR2 stimulation 470nm for specific specific independent excitation in specific specific same neuron from specific specific two-photon 920nm jRGECO1a + specific specific one-photon 470nm ChR2 from specific specific µ LED array for specific specific single-cell precision; specific specific closed-loop seizure detection+suppression: specific specific ECoG epileptic HFO high-frequency oscillation detector from specific specific 80-250 Hz power threshold from specific specific <5ms trigger latency for specific specific AAV-NpHR inhibitory optogenetics from specific specific triggered light pulse 580nm 5-10 mW for specific specific focal seizure suppression from specific specific rodent kindling model >80% reduction); CHEMOGENETICS DREADD PATENTS: BRYAN ROTH UNC; INSERM; JANSSEN: specific DREADD (specific specific hM4Di DREADD: specific specific human muscarinic M4 receptor mutated from specific specific Y3.33C+A5.46G mutations from specific specific CNO clozapine-N-oxide 1-10 mg/kg IP from specific specific Gi-coupled cAMP inhibition for specific specific neuronal inhibition without specific specific opsin or specific specific light delivery for specific specific simpler in vivo experiment at specific specific multiple brain regions simultaneously; specific specific DREADD vs. optogenetics: specific specific pharmacological 0.5-2h time scale vs. specific specific ms optogenetics for specific specific chronic circuit modulation vs. specific specific acute precise timing; specific specific DCZ deschloroclozapine: specific specific 10× lower dose vs. specific specific CNO from specific specific better CNS penetration for specific specific primate DREADD activation from specific specific 0.1 mg/kg SC from specific specific >90% DREADD occupancy at specific specific no endogenous receptor cross-reactivity).

Optogenetics startup IP strategy must understand that MIT Boyden and Stanford Deisseroth hold foundational opsin IP exclusively licensed to Optogenix and Coherent respectively; recognize that therapeutic applications particularly retinal optogenetics have open licensing terms from these foundational patents; identify innovation opportunities in novel opsin proteins, delivery systems, and light delivery hardware; and appreciate the clinical regulatory pathway as a significant complementary moat: OPTOGENETICS STARTUP IP STRATEGY: UNDERSTAND THE OPTOGENETICS IP LANDSCAPE: BOYDEN MIT AND DEISSEROTH STANFORD HOLD FOUNDATIONAL OPSIN IP: The MIT/Boyden (200+) and Stanford/Deisseroth (200+) groups filed the original channelrhodopsin optogenetics patents — the Boyden patents are exclusively licensed to Optogenix and the Deisseroth patents are exclusively licensed to Coherent (formerly II-VI); any commercial optogenetics product requires a license from these two institutions unless using sufficiently different opsin variants; RETINAL OPTOGENETICS HAS FAVORABLE LICENSING: For retinal gene therapy optogenetics specifically, MIT and Stanford have made licensing more accessible — GenSight GS030 (ChrimsonR), Nanoscope Therapeutics (MCO-010), and RetroSense (CoChR) have all obtained retinal optogenetics licenses; THERAPEUTIC APPLICATIONS ARE LESS DENSELY PATENTED: Research tool optogenetics (reagents, systems for neuroscience experiments) has become relatively open, but therapeutic optogenetics for specific indications (RP, Parkinson, epilepsy, pain) still has significant whitespace in novel opsin+delivery+device combination patents; DEVICE IP IS POTENTIALLY MORE DEFENSIBLE: Implantable μLED arrays, wireless NFC-powered optogenetics implants, and closed-loop recording+stimulation systems are potentially more defensible device IP than opsin protein patents; WHEN TO PATENT IN OPTOGENETICS: NOVEL OPSIN VARIANT WITH MEASURED SPECTRAL AND KINETIC PROPERTIES: specific novel opsin protein (specific specific mutation profile + specific specific protein sequence or specific specific chimeric design) with specific measured absorption spectrum peak nm + specific specific off-kinetics τoff ms at specific specific temperature + specific specific photocurrent density pA/pF at specific specific light intensity mW/mm² + specific specific expression level relative fluorescence units/cell vs. specific specific ChR2, ChrimsonR, or specific specific NpHR3.0 baseline measured in specific specific same expression system (specific specific HEK293T or specific specific primary neuron at specific specific same AAV titer and specific specific same illumination protocol); NOVEL LIGHT DELIVERY DEVICE WITH MEASURED SPATIAL AND TEMPORAL RESOLUTION: specific novel optical probe design (specific specific μLED geometry + specific specific substrate + specific specific CMOS integration) with specific measured spatial resolution μm (specific specific nearest-neighbor crosstalk between specific specific adjacent μLED pixels) + specific specific temporal resolution μs (specific specific rise/fall time at specific specific target irradiance mW/mm²) + specific specific biocompatibility (specific specific in vivo stability weeks after specific specific implantation measured by specific specific impedance change and specific specific histology) vs. specific specific tapered fiber or specific specific Neuropixels probe baseline; NOVEL AAV DELIVERY SYSTEM WITH MEASURED TRANSDUCTION EFFICIENCY AND CELL-TYPE SPECIFICITY: specific novel AAV capsid or specific specific promoter combination with specific measured transduction efficiency % at specific specific brain region + specific specific cell-type specificity % target/off-target cells + specific specific immune response NAb titer at specific specific dose in specific specific NHP vs. specific specific AAVPHP.eB or specific specific AAV9 with specific specific CaMKII promoter baseline; CLINICAL MOAT: FDA RMAT Regenerative Medicine Advanced Therapy designation for retinal optogenetics gene therapies provides significant regulatory competitive moat; filing a BLA with optogenetics clinical data for a specific indication establishes an efficacy moat even without composition patent; § 101: opsin protein = composition of matter; AAV delivery = composition + process; light delivery device = hardware; closed-loop algorithm = anchor to specific electrode measurement+light pulse actuation; KEY FTO CHECKLIST: MIT/Boyden Optogenix ChR2/ChRmine soma-targeted MTS ER-export soma compartment restriction; Stanford/Deisseroth Coherent NpHR3.0 eNpHR 580nm Cl⁻ pump; SFO C128S bistable ChIEF 30× faster >100 Hz; AAV-PHP.eB IV BBB crossing >50% cortex; CaMKII 1.3kb excitatory pyramidal neuron-specific; GenSight GS030 AAV2 intravitreal CAG ChrimsonR RGC RP Phase 3; Bryan Roth UNC hM4Di DREADD CNO Gi-coupled DCZ 0.1 mg/kg.